CRIS - Curis, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
1.45
+0.02 (+1.40%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close1.43
Open1.44
Bid1.35 x 900
Ask1.65 x 1000
Day's Range1.43 - 1.49
52 Week Range1.40 - 11.35
Volume69,907
Avg. Volume423,439
Market Cap48.113M
Beta0.80
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
All
News
Press Releases
  • PR Newswire16 days ago

    Curis Reports Second Quarter 2018 Financial Results

    -- Management to host conference call today at 8:30 a.m. EDT -- LEXINGTON, Mass. , Aug. 2, 2018 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development and commercialization ...

  • PR Newswire22 days ago

    Curis to Release Second Quarter Financial Results and Hold Conference Call on August 2, 2018

    LEXINGTON, Mass., July 27, 2018 /PRNewswire/ -- Curis, Inc. (CRIS), a biotechnology company focused on the development and commercialization of innovative and effective therapeutics for the treatment of cancer, today announced that the Company will release its second quarter 2018 financial results on Thursday, August 2, 2018, before the U.S. financial markets open. The Company's management will also host a conference call on the same day at 8:30 a.m. EDT. Curis is a biotechnology company focused on the development and commercialization of innovative therapeutics for the treatment of cancer, including fimepinostat, which is being investigated in clinical studies in patients with DLBCL and solid tumors. Curis is also engaged in a collaboration with Aurigene in the areas of immuno-oncology and precision oncology. As part of this collaboration, Curis has exclusive licenses to oral small molecule antagonists of immune checkpoints including, the PDL1/VISTA antagonist CA-170, and the PDL1/TIM3 antagonist CA-327, as well as the IRAK4 kinase inhibitor, CA-4948. CA-170 is currently undergoing testing in a Phase 1 trial in patients with advanced solid tumors and lymphomas, and in a Phase 2 trial in India conducted by Aurigene.

  • GlobeNewswire23 days ago

    Consolidated Research: 2018 Summary Expectations for At Home Group, Royal Bank Of Canada, Curis, Novavax, HNI, and Freshpet — Fundamental Analysis, Key Performance Indications

    NEW YORK, July 26, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of At ...

  • PR Newswirelast month

    Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    LEXINGTON, Mass., July 9, 2018 /PRNewswire/ -- Curis, Inc. (CRIS), a biotechnology company focused on the development and commercialization of innovative therapeutics for the treatment of cancer, today announced that on July 2, 2018, the independent Compensation Committee of the Board of Directors of Curis approved the grant of inducement stock options to purchase 12,000 shares of Curis common stock to a new employee, with a grant date of July 2, 2018 (the "Q3 2018 Inducement Grant"). Curis is a biotechnology company focused on the development and commercialization of innovative therapeutics for the treatment of cancer, including fimepinostat, which is being investigated in clinical studies in patients with DLBCL and solid tumors.  Curis is also engaged in a collaboration with Aurigene in the areas of immuno-oncology and precision oncology.  As part of this collaboration, Curis has exclusive licenses to oral small molecule antagonists of immune checkpoints including, the PDL1/VISTA antagonist CA-170, and the PDL1/TIM3 antagonist CA-327, as well as the IRAK4 kinase inhibitor, CA-4948.  CA-170 is currently undergoing testing in a Phase 1 trial in patients with advanced solid tumors and lymphomas, and in a Phase 2 trial in India conducted by Aurigene.  CA-4948 is currently undergoing testing in a Phase 1 trial in patients with non-Hodgkin lymphoma.  Curis is also party to a collaboration with Genentech, a member of the Roche Group, under which Genentech and Roche are commercializing Erivedge® for the treatment of advanced basal cell carcinoma.

  • ACCESSWIRE3 months ago

    Curis Shares Show Recent Gains, Pipeline Review and FDA Decision

    NEW YORK, NY / ACCESSWIRE / June 1, 2018 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report with no obligation on Curis, Inc. (CRIS) is a biotechnology company, focused on the development and commercialization of drug candidates for the treatment of human cancers. Curis announced that its previously disclosed 1-for-5 reverse stock split will be effective as of 5:00 p.m. Eastern Time today, May 29, 2018. Curis's common stock will begin trading on the Nasdaq Global Market on a split-adjusted basis when the market opened on Wednesday, May 30, 2018.

  • PR Newswire3 months ago

    /C O R R E C T I O N -- Curis, Inc./

    In the news release, Curis Announces FDA Fast Track Designation for Fimepinostat (CUDC-907) Development in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma, issued 31-May-2018 by Curis, ...

  • PR Newswire3 months ago

    Curis Announces Effectiveness of 1-for-5 Reverse Stock Split

    LEXINGTON, Mass., May 29, 2018 /PRNewswire/ -- Curis, Inc. (CRIS), a biotechnology company focused on the development and commercialization of innovative and effective therapeutics for the treatment of cancer, today announced that its previously disclosed 1-for-5 reverse stock split will be effective as of 5:00 p.m. Eastern Time today, May 29, 2018.  Curis's common stock will begin trading on the Nasdaq Global Market on a split-adjusted basis when the market opens on Wednesday, May 30, 2018.  The new CUSIP number for Curis's common stock following the reverse stock split is 231269 200. The reverse stock split affects all issued and outstanding shares of Curis's common stock, as well as the number of shares of common stock available for issuance under the Company's equity incentive plans.  The reverse stock split will reduce the number of shares of the Curis's issued and outstanding common stock from approximately 337,500,000 million to approximately 67,500,000 million.  In addition, the reverse stock split will effect a reduction in the number of shares of common stock issuable upon the exercise of stock options outstanding immediately prior to the reverse stock split, with a proportional increase in exercise price.  The reverse stock split will proportionately reduce the number of authorized shares of common stock.

  • PR Newswire3 months ago

    Curis Expands Senior Management Expertise with Appointment of Robert Martell, M.D., Ph.D., as Head of Research and Development

    LEXINGTON, Mass., May 24, 2018 /PRNewswire/ -- Curis, Inc. (CRIS), a biotechnology company focused on the development and commercialization of innovative and effective therapeutics for the treatment of cancer, today announced that Robert Martell, M.D., Ph.D., has been appointed Head of Research and Development. In this newly created role, Dr. Martell, a practicing oncologist and experienced drug developer, will directly manage the day-to-day operations of the Curis clinical development and research efforts. Dr. Martell is a member of the Board of Directors of Curis, and will resign from his board duties simultaneous with his start date on June 1st.

  • PR Newswire3 months ago

    Curis Announces 1-for-5 Reverse Stock Split

    LEXINGTON, Mass., May 22, 2018 /PRNewswire/ -- Curis, Inc. (CRIS), a biotechnology company focused on the development and commercialization of innovative and effective therapeutics for the treatment of cancer, today announced that its Board of Directors approved a 1-for-5 reverse split of Curis's common stock that is expected to take effect on Tuesday, May 29, 2018 after the close of trading. The reverse stock split will affect all holders of common stock uniformly and will not alter any stockholder's percentage ownership interest in Curis, except to the extent that the reverse stock split would result in a stockholder owning a fractional share.

  • GlobeNewswire3 months ago

    Factors of Influence in 2018, Key Indicators and Opportunity within MSA Safety Incorporated, Curis, American States Water, AAC, eHealth, and Vista Gold — New Research Emphasizes Economic Growth

    NEW YORK, May 21, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of MSA ...

  • PR Newswire4 months ago

    Curis Reports First Quarter 2018 Financial Results

    -- Management to host conference call today at 8:30 a.m. EDT -- LEXINGTON, Mass. , May 3, 2018 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development and commercialization ...

  • PR Newswire4 months ago

    Curis to Release First Quarter 2018 Financial Results and Hold Conference Call on May 3, 2018

    LEXINGTON, Mass., April 26, 2018 /PRNewswire/ -- Curis, Inc. (CRIS), a biotechnology company focused on the development and commercialization of innovative and effective therapeutics for the treatment of cancer, today announced that the Company will release its first quarter 2018 financial results on Thursday, May 3, 2018, before the U.S. financial markets open. The Company's management will also host a conference call on the same day at 8:30 a.m. EDT. Curis is a biotechnology company focused on the development and commercialization of innovative and effective drug candidates for the treatment of human cancers, including CUDC-907, which is being investigated in clinical studies in patients with lymphomas and solid tumors.

  • ACCESSWIRE4 months ago

    Free Post Earnings Research Report: Curis’ Quarterly Revenue Jumped 38.10%

    Stock Monitor: Aldeyra Therapeutics Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 19, 2018 / Active-Investors.com has just released a free earnings report on Curis, Inc. (NASDAQ: CRIS ). If you ...

  • PR Newswire4 months ago

    Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    LEXINGTON, Mass., April 6, 2018 /PRNewswire/ -- Curis, Inc. (CRIS), a biotechnology company focused on the development and commercialization of innovative and effective drug candidates for the treatment of human cancers, today announced that on April 2, 2018, the independent Compensation Committee of the Board of Directors of Curis approved the grant of inducement stock options to purchase a total of 250,000 shares of Curis common stock to three new employees, with a grant date of April 2, 2018 (the "Q2 2018 Inducement Grants").

  • ACCESSWIRE5 months ago

    Curis, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / March 8, 2018 / Curis, Inc. (NASDAQ: CRIS ) will be discussing their earnings results in their Q4 Earnings Call to be held on March 8, 2018 at 8:30 AM Eastern Time. To listen ...

  • PR Newswire5 months ago

    Curis Reports Fourth Quarter and Year-End 2017 Financial Results

    -- Management to host conference call today at 8:30 a.m. EST -- LEXINGTON, Mass. , March 8, 2018 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development and commercialization ...

  • PR Newswire5 months ago

    Curis to Present at Cowen & Company 38th Annual Health Care Conference

    LEXINGTON, Mass. , March 5, 2018 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development and commercialization of innovative and effective therapeutics for the treatment ...

  • PR Newswire6 months ago

    /C O R R E C T I O N -- Curis, Inc./

    In the news release, Curis to Release Fourth Quarter and Year-End 2017 Financial Results and Hold Conference Call on March 8, 2018 , issued 01-Mar-2018 by Curis, Inc. over PR Newswire, we are advised by ...

  • PR Newswire7 months ago

    Curis Announces Initiation of Phase 1 Trial of CA-4948, a Small Molecule Inhibitor of IRAK4 Kinase in Patients with Lymphoma

    The dose escalation stage of the trial will enroll patients with relapsed/refractory non-Hodgkin's lymphoma, and the expansion stage will focus on specific populations of patients with lymphomas harboring alterations in the MYD88 gene or Toll-like receptor (TLR) signaling pathway. "We are pleased to announce the advancement of our clinical pipeline with the initiation of the Phase 1 trial for this selective IRAK kinase inhibitor in patients with lymphomas," commented Ali Fattaey, Ph.D., Curis's president and CEO.

  • ACCESSWIRE9 months ago

    Curis, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / November 7, 2017 / Curis, Inc. (NASDAQ: CRIS ) will be discussing their earnings results in their Q3 Earnings Call to be held on November 7, 2017 at 8:30 AM Eastern Time. To ...

  • ACCESSWIRE9 months ago

    Curis, Upcoming SITC Meeting, Aurigene Collaboration and Analysts Review

    NEW YORK, NY / ACCESSWIRE / November 6, 2017 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive ...